Release Details

CARLSBAD, Calif., May 14, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announces the following webcast:

    What:     Isis Pharmaceuticals to provide a general corporate update in
              conjunction with the 2007 Annual Meeting of Stockholders.  The
              corporate update will be presented by Stanley T. Crooke, M.D.,
              Ph.D., Chairman and Chief Executive Officer of Isis.

    When:     Thursday, May 17, 2007, at 12:15 p.m. ET / 9:15 a.m. PT

    Where:    www.isispharm.com

    How:      Live on the Internet.  Simply log onto our website listed above.

    Contact:  Kate Corcoran, Ph.D.
              Vice President, Corporate Development
              (760) 603-2331

If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at www.isispharm.com.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 17 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing drugs for cancer, and inflammatory and other diseases. Ibis Biosciences, Inc., Isis' wholly owned subsidiary, is developing and commercializing the Ibis T5000 Biosensor System, a revolutionary system to identify infectious organisms. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,500 issued patents worldwide. Additional information about Isis is available at www.isispharm.com.

SOURCE Isis Pharmaceuticals, Inc.

Kate Corcoran, Ph.D., Vice President, Corporate Development of Isis Pharmaceuticals,
Inc., +1-760-603-2331

http://www.isispharm.com

Copyright (C) 2007 PR Newswire. All rights reserved

News Provided by COMTEX